How to Get Oral Micronized Progesterone in Illinois

Why Oral Micronized Progesterone Is Prescribed

Oral micronized progesterone protects the uterine lining from estrogen-driven hyperplasia in women receiving menopausal hormone therapy. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial (N=875) demonstrated that micronized progesterone paired with conjugated equine estrogens raised HDL cholesterol more favorably than medroxyprogesterone acetate (MPA) while still preventing endometrial hyperplasia over 36 months 1. That finding shifted clinical practice.

The FDA-approved labeling for Prometrium lists two indications: prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens, and treatment of secondary amenorrhea 2. Prometrium was originally manufactured by Solvay Pharmaceuticals and is now available in generic form from several manufacturers. The Endocrine Society's 2015 clinical practice guideline on menopausal HRT recommends micronized progesterone over synthetic progestins for most women with a uterus, citing a more favorable cardiovascular and breast safety profile 3. A 2019 Cochrane review of progestogens in HRT confirmed equivalent endometrial protection between micronized progesterone at adequate doses and synthetic progestins 4.

Who Can Prescribe in Illinois

Any clinician holding an active Illinois prescribing license can write a progesterone prescription. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Illinois NPs gained full practice authority under Public Act 100-0513 in 2018, meaning they can evaluate, diagnose, and prescribe hormone therapy without a collaborative agreement after meeting experience requirements. PAs prescribe under physician supervision per Illinois Medical Practice Act guidelines.

Board certification in endocrinology or menopause medicine is not required to prescribe progesterone, though the North American Menopause Society (NAMS) offers a Certified Menopause Practitioner credential that signals specialized training 5. For patients seeking a provider with HRT expertise, NAMS maintains a searchable directory on its website. The American College of Obstetricians and Gynecologists (ACOG) also publishes practice bulletins endorsing micronized progesterone for endometrial protection in menopausal HRT 6.

Telehealth Prescribing in Illinois

Illinois law permits telehealth prescribing for oral micronized progesterone. The state's Telehealth Act (Public Act 102-0104) allows licensed providers to establish a patient-provider relationship via synchronous audio-video visits. No in-person visit is required before prescribing hormone therapy, as long as the standard of care is met during the virtual encounter.

The practical benefit is significant. Patients in rural counties, such as those in southern or western Illinois far from endocrinology practices concentrated in Chicago and its suburbs, can access HRT prescribing without a multi-hour drive. A 2022 cross-sectional study found that telehealth HRT consultations produced equivalent patient satisfaction and clinical outcomes compared with in-person visits over 12 months 7. During the virtual visit, the prescribing clinician will review symptoms, medical history, and contraindications. The clinician then sends the prescription electronically to the patient's chosen pharmacy.

HealthRX and similar telehealth platforms licensed in Illinois can prescribe oral micronized progesterone after a structured intake and synchronous consultation. Prescriptions are typically transmitted within hours of the visit.

Labs Required Before Starting

No single lab panel is universally mandated by Illinois law before prescribing progesterone. Clinical guidelines, however, recommend baseline testing to rule out contraindications and confirm menopausal status. The Endocrine Society guideline recommends measuring follicle-stimulating hormone (FSH) and estradiol in women whose menopausal status is uncertain 3.

Most prescribers in Illinois will order the following before initiating HRT that includes progesterone:

• FSH and estradiol to confirm menopause in women under 50 or with ambiguous symptoms
• Comprehensive metabolic panel (CMP) to assess liver function, since oral progesterone undergoes hepatic first-pass metabolism 2
• Lipid panel for cardiovascular risk stratification, consistent with PEPI trial monitoring protocols 1
• TSH to exclude thyroid dysfunction as a cause of symptoms mimicking menopause
• CBC as a general screening measure

The USPSTF recommends mammography screening every two years for women aged 50 to 74 8, and most prescribers will confirm that breast cancer screening is current before initiating any HRT regimen. Endometrial assessment via transvaginal ultrasound is not required at baseline in asymptomatic women, but the ACOG practice bulletin on endometrial cancer recommends evaluation if abnormal uterine bleeding is present before starting therapy 6.

Pharmacy Options: Retail and 503A Compounding

Illinois patients can fill progesterone prescriptions at any licensed retail pharmacy. Walgreens, CVS, and independent pharmacies across the state stock generic micronized progesterone capsules (100 mg and 200 mg). Typical retail cash price for a 30-day supply of generic progesterone 200 mg ranges from $25 to $60 without insurance, based on GoodRx pricing data for Illinois zip codes.

Brand-name Prometrium costs more. One important clinical detail: Prometrium capsules contain peanut oil as an excipient 2. Patients with peanut allergy should not take the branded product.

For patients requiring a peanut-free formulation or a non-standard dose, Illinois-licensed 503A compounding pharmacies can prepare micronized progesterone capsules from USP-grade powder. Under FDA guidance, 503A pharmacies compound pursuant to individual patient prescriptions and must hold a valid Illinois Department of Financial and Professional Regulation (IDFPR) pharmacy license 9. The Illinois Pharmacy Practice Act permits 503A compounding, and these pharmacies may ship within the state.

503B outsourcing facilities, which compound without individual prescriptions, are a separate category regulated directly by the FDA under Section 503B of the Federal Food, Drug, and Cosmetic Act 10. Some 503B facilities ship nationwide, including to Illinois. Prescribers who use 503B-sourced progesterone should verify the facility's FDA registration status.

Illinois Medicaid Coverage and Prior Authorization

Illinois Medicaid (administered through managed care organizations including Meridian, Molina, and Blue Cross Blue Shield Community Health Plan) covers oral micronized progesterone for its FDA-approved indication of endometrial protection during estrogen-based HRT. Coverage requires prior authorization (PA).

The PA process in Illinois typically requires the prescriber to submit:

• Clinical documentation confirming the patient has a uterus and is receiving concomitant estrogen therapy
• Diagnosis codes (ICD-10: N95.1 for menopausal and female climacteric states; Z79.890 for long-term HRT use)
• Lab results supporting menopausal status if the patient is under age 50
• Attestation that the patient has no contraindications listed in the FDA labeling, including known or suspected breast cancer, undiagnosed abnormal genital bleeding, or active liver disease 2

PA decisions are generally returned within 24 to 72 hours for standard requests. Urgent PAs can be processed within 24 hours. If denied, the prescriber can file a peer-to-peer review or formal appeal through the patient's managed care plan.

For commercial insurance plans in Illinois, most formularies include generic micronized progesterone on Tier 1 or Tier 2, with typical copays of $5 to $25 for a 30-day supply. Brand Prometrium is often placed on Tier 3, requiring higher cost-sharing. The Illinois Department of Insurance oversees appeals for commercial plan coverage denials.

Dosing Protocols

Two dosing schedules are standard for endometrial protection, per the FDA-approved prescribing information [2]:

Cyclic dosing: 200 mg taken orally at bedtime for 12 consecutive days per 28-day cycle, paired with daily conjugated estrogens. This schedule produces a predictable withdrawal bleed in most women. The PEPI trial used this regimen and confirmed endometrial safety over 3 years 1.

Continuous dosing: 100 mg taken orally every night without interruption, paired with continuous estrogen. This approach aims to avoid monthly bleeding. A 2012 randomized trial (N=596) published in Climacteric found that continuous 100 mg micronized progesterone provided adequate endometrial suppression with a lower rate of breakthrough bleeding after 6 months compared with the initial months of therapy 11.

Bedtime administration is standard because oral progesterone produces neurosteroid metabolites (allopregnanolone) that cause dose-dependent drowsiness 12. This sedative effect is clinically useful for perimenopausal women with sleep disruption. A 2018 study in the Journal of Clinical Endocrinology & Metabolism reported that 200 mg oral micronized progesterone improved subjective sleep quality scores by 16% in perimenopausal women compared with placebo 13.

Progesterone should be taken with food to increase bioavailability. The FDA label notes that Cmax increases approximately 17 to 38-fold when taken with food versus fasting 2.

Safety Profile and Contraindications

Oral micronized progesterone carries a different risk profile than synthetic progestins. The French E3N cohort study (N=80,377) followed postmenopausal women for a mean of 8.1 years and found no significant increase in breast cancer risk with estrogen plus micronized progesterone (RR 1.00 to 95% CI 0.83 to 1.22), while estrogen plus synthetic progestins was associated with a statistically significant increase (RR 1.69 to 95% CI 1.50 to 1.91) 14.

The Women's Health Initiative (WHI) used medroxyprogesterone acetate, not micronized progesterone, in its estrogen-plus-progestin arm 15. The WHI results should not be directly extrapolated to micronized progesterone regimens, a distinction the 2022 NAMS position statement explicitly makes 16.

Contraindications per the FDA label include 2:

• Known or suspected breast cancer
• Active deep vein thrombosis, pulmonary embolism, or history of these conditions
• Active arterial thromboembolic disease (stroke, MI)
• Known liver dysfunction or disease
• Known allergy to progesterone or any capsule ingredient (including peanut oil in Prometrium)
• Undiagnosed abnormal genital bleeding

Common side effects include drowsiness (reported in 31% of patients in clinical trials), dizziness (15%), headache (13%), and abdominal bloating (8%) 2.

Timeline: From Consultation to First Dose

The total time from initial consultation to receiving medication in Illinois depends on the prescribing pathway:

Telehealth route: Complete an online intake (same day), attend a synchronous video consultation (scheduled within 1 to 3 days), and receive an e-prescription at a retail pharmacy (filled in 1 to 2 days). Total: approximately 2 to 5 days.

In-person route: Schedule an appointment with a gynecologist or endocrinologist (wait times vary from 1 week to 8 weeks depending on location and provider availability), attend the visit, complete labs, and fill the prescription. Total: 1 to 10 weeks.

If prior authorization is required (Medicaid): Add 1 to 3 business days for standard PA processing after the prescription is submitted.

Compounding pharmacy orders typically require 3 to 7 business days for preparation and shipping within Illinois. Some compounding pharmacies offer expedited turnaround for an additional fee.

Transferring a Prescription to an Illinois Pharmacy

Patients relocating to Illinois can transfer an existing progesterone prescription from an out-of-state pharmacy. Illinois Board of Pharmacy rules permit incoming transfers for non-controlled substances. Progesterone is not a scheduled controlled substance under the Illinois Controlled Substances Act or the federal Controlled Substances Act, so transfers are straightforward.

To transfer, contact the receiving Illinois pharmacy and provide the out-of-state pharmacy's name and phone number. The receiving pharmacist will initiate a pharmacist-to-pharmacist transfer per NABP guidelines [17]. Remaining refills on the original prescription carry over. The transfer typically completes within one business day.

If the original prescription has no refills remaining, the patient will need a new prescription from an Illinois-licensed provider. Telehealth makes this simple: a brief consultation with an Illinois-licensed prescriber can generate a new prescription the same day.